Loading...

Ryman Healthcare

OTCPK:RYHT.Y
Snowflake Description

Established dividend payer and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RYHT.Y
OTCPK
NZ$6B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly in New Zealand and Australia. The last earnings update was 118 days ago. More info.


Add to Portfolio Compare Print
RYHT.Y Share Price and Events
7 Day Returns
2.6%
OTCPK:RYHT.Y
3%
US Healthcare
1.2%
US Market
1 Year Returns
-
OTCPK:RYHT.Y
8.2%
US Healthcare
3%
US Market
RYHT.Y Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ryman Healthcare (RYHT.Y) 2.6% 10.3% - - 39.9% 10%
US Healthcare 3% -5.1% 3.1% 8.2% 28.3% 74%
US Market 1.2% 2.1% 14.6% 3% 39% 43.5%
1 Year Return vs Industry and Market
  • No trading data on RYHT.Y.
  • No trading data on RYHT.Y.
Price Volatility
RYHT.Y
Industry
5yr Volatility vs Market

Value

 Is Ryman Healthcare undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Ryman Healthcare. This is due to cash flow or dividend data being unavailable. The share price is $40.21.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ryman Healthcare's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ryman Healthcare's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:RYHT.Y PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in NZD NZ$0.71
NZSE:RYM Share Price ** NZSE (2019-03-19) in NZD NZ$11.43
United States of America Healthcare Industry PE Ratio Median Figure of 51 Publicly-Listed Healthcare Companies 21.25x
United States of America Market PE Ratio Median Figure of 3,058 Publicly-Listed Companies 17.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ryman Healthcare.

OTCPK:RYHT.Y PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NZSE:RYM Share Price ÷ EPS (both in NZD)

= 11.43 ÷ 0.71

16.09x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ryman Healthcare is good value based on earnings compared to the US Healthcare industry average.
  • Ryman Healthcare is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does Ryman Healthcare's expected growth come at a high price?
Raw Data
OTCPK:RYHT.Y PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 16.09x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
16.9%per year
United States of America Healthcare Industry PEG Ratio Median Figure of 38 Publicly-Listed Healthcare Companies 1.63x
United States of America Market PEG Ratio Median Figure of 2,103 Publicly-Listed Companies 1.48x

*Line of best fit is calculated by linear regression .

OTCPK:RYHT.Y PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 16.09x ÷ 16.9%

0.95x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ryman Healthcare is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Ryman Healthcare's assets?
Raw Data
OTCPK:RYHT.Y PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in NZD NZ$4.11
NZSE:RYM Share Price * NZSE (2019-03-19) in NZD NZ$11.43
United States of America Healthcare Industry PB Ratio Median Figure of 91 Publicly-Listed Healthcare Companies 2.44x
United States of America Market PB Ratio Median Figure of 5,156 Publicly-Listed Companies 1.89x
OTCPK:RYHT.Y PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NZSE:RYM Share Price ÷ Book Value per Share (both in NZD)

= 11.43 ÷ 4.11

2.78x

* Primary Listing of Ryman Healthcare.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ryman Healthcare is overvalued based on assets compared to the US Healthcare industry average.
X
Value checks
We assess Ryman Healthcare's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Ryman Healthcare has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Ryman Healthcare expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ryman Healthcare expected to grow at an attractive rate?
  • Ryman Healthcare's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Ryman Healthcare's earnings growth is expected to exceed the United States of America market average.
  • Ryman Healthcare's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:RYHT.Y Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:RYHT.Y Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 16.9%
OTCPK:RYHT.Y Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 12.3%
United States of America Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
United States of America Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 7.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:RYHT.Y Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in NZD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:RYHT.Y Future Estimates Data
Date (Data in NZD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-03-31 1,131 621
2022-03-31 1,074 560
2021-03-31 491 929 440 3
2020-03-31 434 703 324 3
2019-03-31 386 336 304 3
OTCPK:RYHT.Y Past Financials Data
Date (Data in NZD Millions) Revenue Cash Flow Net Income *
2018-09-30 364 392 355
2018-06-30 353 371 372
2018-03-31 342 349 388
2017-12-31 329 343 380
2017-09-30 315 337 372
2017-06-30 302 330 365
2017-03-31 289 323 357
2016-12-31 281 320 358
2016-09-30 273 316 360
2016-06-30 266 314 333
2016-03-31 260 312 305
2015-12-31 252 294 286

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Ryman Healthcare's earnings are expected to grow by 16.9% yearly, however this is not considered high growth (20% yearly).
  • Ryman Healthcare's revenue is expected to grow by 12.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:RYHT.Y Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Ryman Healthcare Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:RYHT.Y Future Estimates Data
Date (Data in NZD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-03-31 1.24 1.24 1.24 1.00
2022-03-31 1.12 1.12 1.12 1.00
2021-03-31 0.88 1.03 0.60 3.00
2020-03-31 0.65 0.80 0.51 4.00
2019-03-31 0.61 0.79 0.45 4.00
OTCPK:RYHT.Y Past Financials Data
Date (Data in NZD Millions) EPS *
2018-09-30 0.71
2018-06-30 0.74
2018-03-31 0.78
2017-12-31 0.76
2017-09-30 0.74
2017-06-30 0.73
2017-03-31 0.71
2016-12-31 0.72
2016-09-30 0.72
2016-06-30 0.67
2016-03-31 0.61
2015-12-31 0.57

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Ryman Healthcare is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Ryman Healthcare's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ryman Healthcare has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Ryman Healthcare performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ryman Healthcare's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ryman Healthcare's year on year earnings growth rate has been positive over the past 5 years.
  • Ryman Healthcare's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Ryman Healthcare's 1-year earnings growth is negative, it can't be compared to the US Healthcare industry average.
Earnings and Revenue History
Ryman Healthcare's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ryman Healthcare Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:RYHT.Y Past Revenue, Cash Flow and Net Income Data
Date (Data in NZD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 364.10 355.12
2018-06-30 353.10 371.67
2018-03-31 342.10 388.22
2017-12-31 328.64 380.27
2017-09-30 315.17 372.32
2017-06-30 301.95 364.51
2017-03-31 288.73 356.69
2016-12-31 280.63 358.27 0.55
2016-09-30 272.53 359.85 1.10
2016-06-30 266.44 332.63 1.10
2016-03-31 260.36 305.42 1.10
2015-12-31 252.17 286.01 0.96
2015-09-30 243.99 266.59 0.82
2015-06-30 235.23 254.26 0.82
2015-03-31 226.47 241.92 0.82
2014-12-31 219.36 233.12 0.74
2014-09-30 212.25 224.31 0.66
2014-06-30 207.44 209.56 0.66
2014-03-31 202.63 194.81 0.66
2013-12-31 197.44 170.58 0.61
2013-09-30 192.26 146.36 0.55
2013-06-30 186.45 141.54 0.55
2013-03-31 180.64 136.73 0.55
2012-12-31 174.45 133.32 0.28
2012-09-30 168.25 129.91
2012-06-30 161.38 125.34
2012-03-31 154.52 120.77

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Ryman Healthcare has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Ryman Healthcare used its assets less efficiently than the US Healthcare industry average last year based on Return on Assets.
  • Ryman Healthcare's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Ryman Healthcare's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ryman Healthcare has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Ryman Healthcare's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ryman Healthcare's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ryman Healthcare is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ryman Healthcare's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Ryman Healthcare's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ryman Healthcare Company Filings, last reported 5 months ago.

OTCPK:RYHT.Y Past Debt and Equity Data
Date (Data in NZD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 2,052.72 1,223.30
2018-06-30 2,052.72 1,223.30
2018-03-31 1,940.52 1,068.71
2017-12-31 1,940.52 1,068.71
2017-09-30 1,805.45 953.05
2017-06-30 1,805.45 953.05
2017-03-31 1,652.09 845.01
2016-12-31 1,652.09 845.01
2016-09-30 1,462.61 713.95
2016-06-30 1,462.61 713.95
2016-03-31 1,327.53 555.16
2015-12-31 1,327.53 555.16
2015-09-30 1,192.01 502.69 1.72
2015-06-30 1,192.01 502.69 1.72
2015-03-31 1,101.32 411.81 0.41
2014-12-31 1,101.32 411.81 0.41
2014-09-30 1,000.60 391.67 3.83
2014-06-30 1,000.60 391.67 3.83
2014-03-31 926.75 278.95 1.75
2013-12-31 926.75 278.95 1.75
2013-09-30 786.29 234.02 0.61
2013-06-30 786.29 234.02 0.61
2013-03-31 734.47 232.48 0.53
2012-12-31 734.47 232.48 0.53
2012-09-30 691.25 233.92 2.25
2012-06-30 691.25 233.92 2.25
2012-03-31 647.22 219.56 2.77
  • Ryman Healthcare's level of debt (59.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (29.8% vs 59.6% today).
  • Debt is well covered by operating cash flow (32%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 3.1x coverage).
X
Financial health checks
We assess Ryman Healthcare's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ryman Healthcare has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Ryman Healthcare's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.91%
Current annual income from Ryman Healthcare dividends. Estimated to be 2.37% next year.
If you bought $2,000 of Ryman Healthcare shares you are expected to receive $38 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Ryman Healthcare's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.45%).
  • Ryman Healthcare's dividend is below the markets top 25% of dividend payers in United States of America (3.64%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:RYHT.Y Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
United States of America Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 1.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2004 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:RYHT.Y Future Dividends Estimate Data
Date (Data in NZ$) Dividend per Share (annual) Avg. No. Analysts
2023-03-31 0.39 1.00
2022-03-31 0.34 1.00
2021-03-31 0.30 5.00
2020-03-31 0.26 6.00
2019-03-31 0.23 6.00
OTCPK:RYHT.Y Past Annualized Dividends Data
Date (Data in NZ$) Dividend per share (annual) Avg. Yield (%)
2018-05-17 0.218 1.828
2017-11-23 0.190 1.787
2017-06-23 0.186 2.044
2017-05-19 0.186 2.202
2016-11-18 0.170 1.989
2016-06-24 0.170 1.848
2016-05-20 0.170 1.818
2015-11-20 0.146 1.747
2015-06-26 0.146 1.877
2015-05-22 0.146 1.823
2014-11-21 0.126 1.547
2014-06-20 0.124 1.564
2014-05-15 0.124 1.469
2013-11-21 0.112 1.383
2013-05-16 0.108 1.567
2012-11-15 0.092 1.929
2012-06-22 0.090 2.369
2012-05-17 0.090 2.653
2011-12-09 0.078 2.677
2011-11-17 0.078 2.979
2011-06-24 0.076 2.911
2011-05-19 0.076 2.792
2010-11-17 0.068 2.877
2010-05-19 0.061 2.933
2009-11-23 0.056 2.673
2009-05-21 0.053 2.987
2009-03-23 0.052 3.554

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Ryman Healthcare's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3.3x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (2x coverage).
X
Income/ dividend checks
We assess Ryman Healthcare's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ryman Healthcare afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ryman Healthcare has a total score of 5/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Ryman Healthcare's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Gordon MacLeod
COMPENSATION NZ$991,867
TENURE AS CEO 1.7 years
CEO Bio

Mr. Gordon MacLeod has been the Chief Executive Officer since July 1, 2017 of Ryman Healthcare Limited since October 26, 2006 and serves as its Secretary and served as its Deputy Chief Executive and Chief Financial Officer. Mr. MacLeod is responsible for investor relations, treasury management, planning and budgeting, financial and management reporting, IT and systems development, taxation compliance, aged care billing and insurances. He served as a Corporate Finance Partner of PricewaterhouseCoopers and also served as the Finance Director of a London listed hi-tech engineering company based in Cambridge, England. He serves as a Director of Rowena Jackson Retirement Village Limited, Malvina Major Retirement Village Limited and Essie Summers Retirement Village Limited. Mr. MacLeod holds a Bachelor of Commerce from the University of Canterbury and is a Chartered Accountant.

CEO Compensation
  • Insufficient data for Gordon to compare compensation growth.
  • Gordon's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure of the Ryman Healthcare management team in years:

1.8
Average Tenure
  • The average tenure for the Ryman Healthcare management team is less than 2 years, this suggests a new team.
Management Team

Gordon MacLeod

TITLE
CEO & Secretary
COMPENSATION
NZ$992K
TENURE
1.7 yrs

Simon Challies

TITLE
Advisor to the Board
COMPENSATION
NZ$3M
TENURE
1.8 yrs

David Bennett

TITLE
Chief Financial Officer
TENURE
1.8 yrs

Barbara Reynen-Rose

TITLE
Chief Operating Officer

Nicole Forster

TITLE
Chief People & Technology Officer

Debbie Versey McClure

TITLE
Chief Sales & Marketing Officer
TENURE
2.3 yrs

Andrew Mitchell

TITLE
Chief Development Officer

Tom Brownrigg

TITLE
Chief Construction Officer

Jenn Poskitt

TITLE
Group Health & Safety Manager
Board of Directors Tenure

Average tenure of the Ryman Healthcare board of directors in years:

5.3
Average Tenure
  • The tenure for the Ryman Healthcare board of directors is about average.
Board of Directors

David Kerr

TITLE
Chairman of the Board
COMPENSATION
NZ$207K
TENURE
20.2 yrs

Warren Bell

TITLE
Deputy Chairman
COMPENSATION
NZ$120K

Claire Higgins

TITLE
Non-Executive Director
COMPENSATION
NZ$131K
TENURE
4.5 yrs

Jo Appleyard

TITLE
Non-Executive Director
COMPENSATION
NZ$103K
TENURE
10.2 yrs

George Savvides

TITLE
Non-Executive Director
COMPENSATION
NZ$131K
TENURE
6.2 yrs

Geoffrey Cumming

TITLE
Director
TENURE
0.8 yrs

Anthony Leighs

TITLE
Independent Director
AGE
47
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Ryman Healthcare's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ryman Healthcare has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly in New Zealand and Australia. Its villages offer a range of retirement living and care options, such as independent townhouses and apartments, and serviced apartments, as well as a care center, which provides rest homes, hospitals, and dementia level care. The company’s villages also offer lounges and bar, indoor swimming pool and spa, gym, beauty salon, bowling green, library, Internet café, movie theatre, and other facilities. As of November 23, 2018, it owned and operated 33 retirement villages and serves 11,000 residents. The company was founded in 1984 and is based in Christchurch, New Zealand.

Details
Name: Ryman Healthcare Limited
RYHT.Y
Exchange: OTCPK
Founded: 1984
NZ$3,895,947,314
497,679,149
Website: http://www.rymanhealthcare.co.nz
Address: Ryman Healthcare Limited
Airport Business Park,
92 Russley Road,
Christchurch,
8042,
New Zealand
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NZSE RYM Ordinary Shares New Zealand Stock Exchange NZ NZD 29. Jun 1999
OTCPK RHCG.F Ordinary Shares Pink Sheets LLC US USD 29. Jun 1999
DB RH7 Ordinary Shares Deutsche Boerse AG DE EUR 29. Jun 1999
OTCPK RYHT.Y ADR REPSTG 5 SHS Pink Sheets LLC US USD 09. Nov 2011
Number of employees
Current staff
Staff numbers
5,000
Ryman Healthcare employees.
Industry
Health Care Facilities
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/21 00:34
End of day share price update: 2019/03/19 00:00
Last estimates confirmation: 2019/03/13
Last earnings filing: 2018/11/23
Last earnings reported: 2018/09/30
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.